Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory studyHaoran Xia, Gening Jiang, Han Zhang et al.|Signal Transduction and Targeted Therapy|2024Cited by 30
Utility of 18F-FDG PET/CT uptake values in predicting response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancerFenghui Zhuang, Minglei Yang, Minjie Ma et al.|Lung Cancer|2023Cited by 25
Sleeve resection after neoadjuvant chemoimmunotherapy in the treatment of locally advanced non-small cell lung cancerJie Dai, Gening Jiang, Xinsheng Zhu et al.|Translational Lung Cancer Research|2022Cited by 19
Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trialChengxiang Yi, Peng Zhang, Dongliang Bian et al.|Nature Communications|2025Cited by 13
Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trialDongliang Bian, Peng Zhang, Shuyu Ji et al.|Nature Communications|2025Cited by 11